SCHEMBL17033347

SCHEMBL17033347

O=c1cc2c3ccccc3c3cc(=O)c4cc(Cl)cc1c4n23

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ HPGD P15428 4/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ ALDH1A1 P00352 3/20 0.41
▸ POLB P06746 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HTT P42858 1/20 0.41
▸ TNKS O95271 2/20 0.38
▸ ADORA3 P0DMS8 1/20 0.38
▸ PDE10A Q9Y233 1/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ GABRP O00591 3/20 0.35
▸ GABRD O14764 3/20 0.35
▸ GABRA1 P14867 3/20 0.35
▸ GABRB1 P18505 3/20 0.35
▸ GABRG2 P18507 3/20 0.35
▸ GABRB3 P28472 3/20 0.35
▸ GABRA5 P31644 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18387409 0.85 ADCY1 (0.33) KDM4EHPGDALDH1A1TNKSADORA3
SCHEMBL17033340 0.85 AHR (0.44) KDM4EKMT2AHPGDMEN1ALDH1A1
SCHEMBL17028346 0.84 ALDH1A1 (0.42) KDM4EKMT2AHPGDMEN1ALDH1A1
SCHEMBL17028314 0.81 CYP1A2 (0.38) KDM4EKMT2AHPGDMEN1ALDH1A1
SCHEMBL17133802 0.80 KDM4E (0.46) KDM4EKMT2AHPGDMEN1ALDH1A1
SCHEMBL17028363 0.77 TNKS (0.40) KDM4EKMT2AHPGDMEN1ALDH1A1
SCHEMBL17028356 0.77 KIF11 (0.41) KDM4EHPGDALDH1A1MAPTHTT
SCHEMBL17028360 0.77 PGR (0.40) KMT2AHPGDMEN1ALDH1A1MAPT
SCHEMBL17033208 0.77 PGR (0.40) KDM4EKMT2AHPGDMEN1ALDH1A1
SCHEMBL17033180 0.76 ALDH1A1 (0.36) KDM4EKMT2AHPGDMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170018717-A1 NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-01-19 — — US disclosed
US-20170018717-A1 NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) 2017-01-19 — — US disclosed
WO-2015125125-A1 NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS BASF SE (DE) 2015-08-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170018717-A1 NEW CYCLAZINES AND THEIR USE AS SEMICONDUCTORS CHRM2, RPS4Y1, CHRM4 KDM4E 889/4885KMT2A 675/4885HPGD 4394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback